Altium Capital, founded by Jacob Gottlieb, is now focused on what’s happening in healthcare. This investment fund based out of New York City, is a new venture for Gottlieb. As a private company, Altium is rooted in aggressive research conducted by Jacob Gottlieb himself. What is he looking for most?
Gottlieb wants to look for the most advanced medical treatments available this year, as well as what is emerging in the near future. One of the most recent is now an oral medication that is specifically for those with diabetes. The goal of the pharmaceutical company behind this medication is to replace injections.
Another area in which Altium is seeking an opportunity is the much needed revolution for the FDA that hasn’t yet occurred. Alzheimer’s, a disease that impacts aged adults, has been highly researched, and the FDA continues to release medications that at best can keep symptoms at bay. Although the symptoms may be reduced, there really is cure for the disease.
Because Alzheimer’s affects more than two million individuals per year, it still needs more attention than it’s getting. Altium Capital is hoping to find an opportunity here as the FDA continues to tout the idea that there is one miracle drug that will aid in reducing symptoms of Alzheimer’s. Once the disease leads to dementia, it is more challenging to find answers and research for more options. Once the FDA gives an approval, the drugs can then be tested in clinical trials, as well as in hospitals depending upon the type of drug and what the drug is for.
These drugs are well worth investing in, and Jacob Gottlieb may very well find his niche when it comes to drugs for diseases like Alzheimer’s and diabetes as well. The top diseases that are impacting the lives of those with diabetes and Alzheimer’s are going to be where Altium Capital directs its focus in the near future.